|THC||arthritis,ra via review||The endocannabinoid system and its therapeutic implications in rheumatoid arthritis.||May 2015|
Action Pathway: CB2|
In particular, specific activation of CB2 may relieve RA by inhibiting not only the production of autoantibodies, proinflammatory cytokines, and MMPs, but also bone erosion, immune response mediated by T cells, and the proliferation of FLSs. In this review, we will discuss the possible functions of the endocannabinoid system in the modulation of RA, which may be a potential target for treatment.
|JWH-015||ra,anti-inflamatory in rats via experiment||Cannabinoid Receptor 2 Agonist JWH-015 Inhibits Interleukin-1beta--Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts and in Adjuvant Induced Arthritis Rat via Glucocorticoid Receptor||May 2019|
Action Pathway: GR|
Overall, our findings suggest that CB2 agonist JWH-015 elicits anti-inflammatory effects partly through GR. This compound could further be tested as an adjunct therapy for the management of pain and tissue destruction as a non-opioid for RA.
|cannabinoids||diabetes,ra,ms via review||Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?||May 2019|
Action Pathway: CB1,CB2|
Thus, in this review, we summarize the mechanisms by which CBRs interact with the autoimmune environment and the potential to suppress the development and activation of autoreactive cells. Finally, we highlight how the modulation of CB1R and CB2R is advantageous in the treatment of autoimmune diseases, including multiple sclerosis (MS), type 1 diabetes mellitus (T1DM) and rheumatoid arthritis (RA).
|Cannflavin||ra in vitro||Cannflavin A and B, prenylated flavones from Cannabis sativa L.||Apr 1986|
|Two novel prenylated flavones, termed Cannflavin A and B, were isolated from the cannabinoid free ethanolic extract of Cannabis sativa L. Both compounds inhibited prostaglandin E2 production by human rheumatoid synovial cells in culture.|